Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Timothy Barnes

Director, Enterprise Operations and Director, UCL Advances

T: 020 3108 3282
E: enterprise.ops@ucl.ac.uk

Timothy Barnes

A graduate of UCL, Tim began his professional life as a business consultant with a ‘big five’ firm in London. He has worked as an investment manager at a pan-European investment firm that specialised in early-stage technology ventures, initiating the firm’s university liaison programme, which included members from across Europe. Prior to Advances, he spent six years running his own business, which helped universities and large corporations – including UCL, the BBC and Reuters – to spin-out high technology companies.

Tim joined UCL Advances in August 2007 to lead the department from launch. Since then, it has grown from a four to 20 person unit and has raised over £6 million from funding bodies and other corporate partners, including the Higher Education Council for England (HEFCE) and European Union ERDF.